Performance of D-dimer to lymphocyte ratio in predicting the mortality of COVID-19 patients

Front Cell Infect Microbiol. 2022 Dec 15:12:1053039. doi: 10.3389/fcimb.2022.1053039. eCollection 2022.

Abstract

Background: Nowadays, there is still no effective treatment developed for COVID-19, and early identification and supportive therapies are essential in reducing the morbidity and mortality of COVID-19. This is the first study to evaluate D-dimer to lymphocyte ratio (DLR) as a prognostic utility in patients with COVID-19.

Methods: We retrospectively analyzed 611 patients and separated them into groups of survivors and non-survivors. The area under the curve (AUC) of various predictors integrated into the prognosis of COVID-19 was compared using the receiver operating characteristic (ROC) curve. In order to ascertain the interaction between DLR and survival in COVID-19 patients, the Kaplan-Meier (KM) curve was chosen.

Results: Age (OR = 1.053; 95% CI, 1.022-1.086; P = 0.001), NLR (OR = 1.045; 95% CI, 1.001-1.091; P = 0.046), CRP (OR = 1.010; 95% CI, 1.005-1.016; P < 0.001), PT (OR = 1.184; 95% CI, 1.018-1.377; P = 0.029), and DLR (OR = 1.048; 95% CI, 1.018-1.078; P = 0.001) were the independent risk factors related with the mortality of COVID-19. DLR had the highest predictive value for COVID-19 mortality with the AUC of 0.924. Patients' survival was lower when compared to those with lower DLR (Log Rank P <0.001).

Conclusion: DLR might indicate a risk factor in the mortality of patients with COVID-19.

Keywords: COVID-19; D-dimer; D-dimer to lymphocyte ratio; immunothrombosis; lymphocyte; mortality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19* / diagnosis
  • Fibrin Fibrinogen Degradation Products
  • Humans
  • Lymphocytes
  • Neutrophils
  • Retrospective Studies

Substances

  • fibrin fragment D
  • Fibrin Fibrinogen Degradation Products